Research progress of vascular endothelial growth factor in progression and prognosis of oral squamous cell carcinoma

Abstract

Abstract: Vascular endothelial growth factor (VEGF) has proven to be the most critical angiogenic factor identified to dates, whose family members are composed of 7 ligands, 3 receptors and 2 co-receptors. Through multiple signaling pathways, VEGF shows capacities of promoting vascular endothelial cell proliferation and angiogenesis, lymphatic endothelial cell growth and lymphatic metastasis, and antiapoptotic cell biology effect. Tumor growth, metastasis and prognosis are closely related with VEGF. Newly-born vessels provide nutrition for tumor growth, as well as providing channel for tumor migration. This review focused on the molecular structure of VEGF and its receptors, signal mechanisms, cytology effects, and its relation with progression and prognosis of oral squamous cell carcinoma (OSCC ).

Key words: Vascular endothelial growth factor, Oral squamous cell carcinoma, Signal pathway

CLC Number:

R739.8

MA Hai-long, ZHONG Lai-ping, ZHANG Zhi-yuan. Research progress of vascular endothelial growth factor in progression and prognosis of oral squamous cell carcinoma[J]. China Journal of Oral and Maxillofacial Surgery, 2014, 12(2): 175-178.

References

[1] Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics,2002[J]. CA Cancer J Clin, 2005, 55(2): 74-108.
[2] Yhee JY, Yu CH, Kim JH, et al. Angiogenesis and expression of vascular endothelial growth factor, tumour necrosis factor-α and hypoxia inducible factor-1α in canine renal cell carcinoma [J]. J Comp Pathol, 2012, 147(2-3): 129-138.
[3] Otrock ZK, Makarem JA, Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: review [J]. Blood Cells Mol Dis, 2007, 38(3): 258-268.
[4] Ambasta RK, Sharma A, Kumar P. Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy [J]. Vasc Cell, 2011, 3: 26.
[5] Altmann HK, Gertsch J. Anticancer drugs from nature natural products as a unique source of new microtubule-stabilizing agents [J]. Nat Prod Rep, 2007, 24(2): 327-357.
[6] Shen K, Ji L, Gong C, et al. Notoginsenoside Ft1 promotes angiogenesis via HIF-1α mediated VEGF secretion and the regulation of PI3K/AKT and Raf/MEK/ERK signaling pathways[J]. Biochem Pharmacol, 2012, 84(6): 784-792.
[7] Feng Y, Hu J, Ma J, et al. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways[J]. Eur J Cancer, 2011, 47(15): 2353-2363.
[8] Pan R, Dai Y, Gao XH, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis by scopoletin through interrupting the autophosphorylation of VEGF receptor 2 and its downstream signaling pathways [J]. Vascul Pharmacol, 2011, 54(1-2): 18-28.
[9] Jesmin S, Zaedi S, Islam AM, et al. Time-dependent alterations of VEGF and its signaling molecules in acute lung injury in a rat model of sepsis [J]. Inflammation, 2012, 35(2): 484-500.
[10] van den Akker NM, Caolo V, Molin DG, et al. Cellular decisions in cardiac out ow tract and coronary development: an act by VEGF and NOTCH [J]. Differentiation, 2012, 84(1): 62-78.
[11] Ferrara N. Vascular endothelial growth factor: basic science and clinical progress [J]. Endocr Rev, 2004, 25(4): 581-611.
[12] Miao HQ, Hu K, Jimenez X, et al. Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2 [J]. Biochem Biophys Res Commun, 2006, 345(1): 438-445.
[13] Rius J, Martínez-Gonz&#x0dbc0;&#x0dd61;lez J, Crespo J, et al. NOR-1 is involved in VEGF-induced endothelial cell growth [J]. Atherosclerosis, 2006, 184(2): 276-282.
[14] Bryan BA, Dennstedt E, Mitchell DC, et al. RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis [J]. FASEB J, 2010, 24(9): 3186-3195.
[15] Zhang F, Tang Z, Hou X, et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis [J]. Proc Natl Acad Sci USA, 2009, 106(15): 6152-6157.
[16] Nayak S, Goel MM, Chandra S, et al. VEGF-A immunohistochemical and mRNA expression in tissues and its serum levels in potentially malignant oral lesions and oral squamous cell carcinomas [J]. Oral Oncol, 2012, 48(3): 233-239.
[17] 张从纪,李慧增,周树夏,等.颌面部爆炸伤早期血管内皮生长因子表达的免疫组化分析[J].口腔颌面外科杂志,2000,10(1):20-23.
[18] Liu CJ, Chang KW, Lin SC, et al. Presurgical serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in oral squamous cell carcinoma [J]. Oral Oncol, 2009, 45(10): 920-925.
[19] Seki S, Fujiwara M, Matsuura M, et al. Prediction of outcome of patients with oral squamous cell carcinoma using vascular invasion and the strongly positive expression of vascular endothelial growth factors [J]. Oral Oncol, 2011, 47(7): 588-593.
[20] Cheng SJ, Lee JJ, Cheng SL, et al. Increased serum placenta growth factor level is significantly associated with progression, recurrence and poor prognosis of oral squamous cell carcinoma[J]. Oral Oncol, 2012, 48(5): 424-428.
[21] Cheng SJ, Cheng SL, Lee JJ, et al. Increased placenta growth factor mRNA level is signi cantly associated with progression, recurrence and poor prognosis of oral squamous cell carcinoma[J]. J Formos Med Assoc, 2013, 112(5): 253-258.
[22] Cheng SL, Lee JJ, Kok SH, et al. Expression of vascular endothelial growth factor is significantly associated with progression and prognosis of oral squamous cell carcinomas in Taiwan [J]. J Formos Med Assoc, 2011, 110(1): 50-57.
[23] Korostoff A, Reder L, Masood R, et al. The role of salivary cytokine biomarkers in tongue cancer invasion and mortality [J]. Oral Oncol, 2011, 47(4): 282-287.
[24] Sweeny L, ZimmermannTM, Liu Z, et al. Evaluation of tyrosine receptor kinases in the interactions of head and neck squamous cell carcinoma cells and fibroblasts [J]. Oral Oncol, 2012, 48(12): 1242-1249.
[25] Park SJ, Kim MJ, Kim YK, et al. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma [J]. Cancer Lett, 2010, 292(1): 54-63.
[26] 郭伟. 晚期口腔颌面头颈部鳞癌靶向治疗的进展浅析 [J]. 口腔颌面外科杂志, 2012, 22(2): 77-81.